| Primary |
| Product Used For Unknown Indication |
56.1% |
| Acute Myeloid Leukaemia |
22.7% |
| Acute Leukaemia |
19.7% |
| Leukaemia |
1.5% |
|
| Cytolytic Hepatitis |
17.9% |
| Thrombocytopenia |
10.7% |
| Immunosuppression |
7.1% |
| Septic Shock |
7.1% |
| Acute Respiratory Distress Syndrome |
3.6% |
| Angiodysplasia |
3.6% |
| Coagulation Factor V Level Decreased |
3.6% |
| Colitis |
3.6% |
| Coma |
3.6% |
| Encephalitis |
3.6% |
| Escherichia Test Positive |
3.6% |
| Haemorrhage |
3.6% |
| Hypertriglyceridaemia |
3.6% |
| Liver Abscess |
3.6% |
| Neoplasm Progression |
3.6% |
| Osteitis |
3.6% |
| Pyrexia |
3.6% |
| Renal Failure |
3.6% |
| Streptococcal Sepsis |
3.6% |
| Venoocclusive Liver Disease |
3.6% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
20.1% |
| Acute Myeloid Leukaemia |
18.4% |
| Product Used For Unknown Indication |
14.6% |
| Drug Exposure During Pregnancy |
7.6% |
| Drug Use For Unknown Indication |
7.3% |
| Acute Leukaemia |
5.8% |
| Bronchopulmonary Aspergillosis |
5.2% |
| Pyrexia |
3.5% |
| T-cell Type Acute Leukaemia |
2.5% |
| Lymphocytic Leukaemia |
2.0% |
| Lymphoma |
1.8% |
| Acute Myelomonocytic Leukaemia |
1.7% |
| Leukaemia |
1.4% |
| T-cell Lymphoma |
1.4% |
| Chronic Myeloid Leukaemia |
1.2% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
1.2% |
| Infection |
1.1% |
| Vomiting |
1.1% |
| Acute Lymphoblastic Leukemia |
1.0% |
| Precursor B-lymphoblastic Lymphoma |
1.0% |
|
| Cytolytic Hepatitis |
7.7% |
| Ventricular Fibrillation |
7.7% |
| Septic Shock |
6.7% |
| Thrombocytopenia |
6.7% |
| Toxic Optic Neuropathy |
6.7% |
| Hypertriglyceridaemia |
5.8% |
| Staphylococcal Infection |
5.8% |
| Fungal Infection |
4.8% |
| Premature Baby |
4.8% |
| Pulmonary Embolism |
4.8% |
| Pyrexia |
4.8% |
| Autoimmune Thrombocytopenia |
3.8% |
| Bacterial Sepsis |
3.8% |
| Bone Marrow Failure |
3.8% |
| Dermatitis Exfoliative |
3.8% |
| Febrile Bone Marrow Aplasia |
3.8% |
| Hypertrophic Cardiomyopathy |
3.8% |
| Myocardial Infarction |
3.8% |
| Premature Labour |
3.8% |
| Aplasia |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.1% |
| Drug Use For Unknown Indication |
18.0% |
| Acute Lymphocytic Leukaemia |
9.5% |
| Acute Myeloid Leukaemia |
7.5% |
| Hyperthermia |
4.8% |
| Aplasia |
2.0% |
| Pain |
2.0% |
| Pyrexia |
2.0% |
| Antifungal Prophylaxis |
1.4% |
| Chemotherapy |
1.4% |
| Diabetes Mellitus Non-insulin-dependent |
1.4% |
| Haematological Malignancy |
1.4% |
| Infection |
1.4% |
| Myeloid Leukaemia |
1.4% |
| Nausea |
1.4% |
| Oral Fungal Infection |
1.4% |
| Sepsis |
1.4% |
| Hypertension |
1.0% |
| Intravenous Catheter Management |
1.0% |
| Lung Disorder |
0.7% |
|
| Cytolytic Hepatitis |
12.1% |
| Pulmonary Embolism |
9.1% |
| Sepsis |
9.1% |
| Blood Bilirubin Increased |
6.1% |
| Diabetes Mellitus |
6.1% |
| Hepatosplenomegaly |
6.1% |
| Hyperbilirubinaemia |
6.1% |
| Tachycardia |
6.1% |
| Urinary Retention |
6.1% |
| Cerebellar Haemorrhage |
3.0% |
| Gamma-glutamyltransferase Increased |
3.0% |
| Headache |
3.0% |
| Hepatomegaly |
3.0% |
| International Normalised Ratio Increased |
3.0% |
| Malaise |
3.0% |
| Mucosal Inflammation |
3.0% |
| Neutropenia |
3.0% |
| Prothrombin Time Prolonged |
3.0% |
| Purpura |
3.0% |
| Speech Disorder |
3.0% |
|
